These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 21981437)

  • 1. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
    Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
    Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
    Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
    Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional safety risk to exceptionally approved drugs in Europe?
    Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; Eichler HG; de Graeff PA; Mol PG
    Br J Clin Pharmacol; 2011 Sep; 72(3):490-9. PubMed ID: 21501215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Information for adequate prescribing to older patients : an evaluation of the product information of 53 recently approved medicines.
    Beers E; Egberts TC; Leufkens HG; Jansen PA
    Drugs Aging; 2013 Apr; 30(4):255-62. PubMed ID: 23420118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-approval safety issues with innovative drugs: a European cohort study.
    Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
    Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is patient exposure preapproval and postapproval a determinant of the timing and frequency of occurrence of safety issues?
    Pacurariu AC; Hoeve CE; Arlett P; Genov G; Slattery J; Sturkenboom MCJM; Straus SMJM
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):168-173. PubMed ID: 29278866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands.
    de Vries E; Denig P; de Vries ST; Monster TBM; Hugtenburg JG; Mol PGM
    Drug Saf; 2020 Jul; 43(7):677-690. PubMed ID: 32212054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk minimization activities of centrally authorized products in the EU: a descriptive study.
    Zomerdijk IM; Sayed-Tabatabaei FA; Trifirò G; Blackburn SC; Sturkenboom MC; Straus SM
    Drug Saf; 2012 Apr; 35(4):299-314. PubMed ID: 22339506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison.
    Zeitoun JD; Lefèvre JH; Downing N; Bergeron H; Ross JS
    PLoS One; 2014; 9(10):e109100. PubMed ID: 25333986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-marketing safety-related regulatory actions on first-in-class drugs: A double-cohort study.
    Ikeda J; Kaneko M; Narukawa M
    J Clin Pharm Ther; 2020 Jun; 45(3):496-502. PubMed ID: 31846100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval.
    Bertele' V; Assisi A; Di Muzio V; Renzo D; Garattini S
    Eur J Clin Pharmacol; 2007 Sep; 63(9):879-89. PubMed ID: 17646975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Br J Clin Pharmacol; 2015 Oct; 80(4):716-26. PubMed ID: 25808713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNF-α Inhibitors.
    Minnema LA; Giezen TJ; Hoekman J; Egberts TCG; Leufkens HGM; Gardarsdottir H
    Clin Pharmacol Ther; 2021 Jul; 110(1):123-131. PubMed ID: 33278830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissemination of Direct Healthcare Professional Communications on Medication Errors for Medicinal Products in the EU: An Explorative Study on Relevant Factors.
    Hoeve CE; de Vries E; Mol PGM; Sturkenboom MCJM; Straus SMJM
    Drug Saf; 2021 Jan; 44(1):73-82. PubMed ID: 33355904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
    Ikeda J; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of safety-related regulatory action on clinical practice: a systematic review.
    Piening S; Haaijer-Ruskamp FM; de Vries JT; van der Elst ME; de Graeff PA; Straus SM; Mol PG
    Drug Saf; 2012 May; 35(5):373-85. PubMed ID: 22480319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.